anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a system and method for integrating emotion data into a social network platform and share the emotion data over the social network platform connected through a communication network. The method includes the step of collecting biorhythm data of the user through a wearable user device. The method includes the step of receiving the biorhythm data of the users through a computing device communicatively connected with the wearable user device over the communication network. The method includes the step of integrating the emotion data through an integration module. The method includes the step of determining an emotional state of the user through an emotional state determination module. The method includes the step of analyzing and displaying emotional data of the users in real-time through an emotional data displaying module.
Participants will receive durvalumab dose A administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w). Thereafter, durvalumab monotherapy will be continued every 4 weeks post-chemotherapy unless specific treatment discontinuation criteria are met.
Instances of claim data are received by an apparatus. Each instance of claim data corresponds to an entity. A claim vector is generated for each instance of claim data. The claim vector is added to a group of claim vectors that all correspond to a same entity. Each group of claim vectors is aggregated to generate an entity vector corresponding to the entity. Based at least in part on the entity vector and (a) an entity profile corresponding to the corresponding entity or (b) an entity cluster with which the entity is associated, at least one behavior signal value is determined for the entity. A behavior signal is amended to include the behavior signal value. The behavior signal comprises at least two behavior signal values. Each of the behavior signal values are associated with a different time period. The behavior signal is provided for display and/or further processing.
A medical practitioner can specify certain parameters for a procedure that involves delivering a therapeutic agent, while leaving other parameters open. The therapeutic agent can be sensitive to biomechanical forces (or other influences) associated with delivery. The procedure can involve regenerative medicine, for example delivering progenitor or stem cells to a diseased heart using a catheter, whereby unbridled transport in the catheter may compromise efficacy. The open parameters can influence efficacy of the agent and thus therapeutic outcome. A computer-based system can apply stored information, such as from databases, to narrow the possible values of the open parameters. From the narrowed possibilities, an optimization routine can determine suitable or optimized values for the open parameters. The determined values can manage biomechanical forces incurred by the therapeutic agent, thereby promoting efficacy and healing. The optimized parameters can guide the practitioner in the procedure.
Human papillomavirus (HPV) infections account for several human cancers. There is an urgent need to develop therapeutic vaccines for targeting preexisting high-risk HPV (such as HPV 16 and 18) infections and lesions, which are insensitive to preventative vaccines. In this study, we developed a lipid nanoparticle-formulated mRNA-based HPV therapeutic vaccine (mHTV), mHTV-02, targeting the E6/E7 of HPV16 and HPV-18. mHTV-02 dramatically induced antigen-specific cellular immune response and robust memory T-cell immunity in mice, besides significant CD8+ T-cell infiltration and cytotoxicity in TC-1 tumors expressing HPV E6/E7, resulting in tumor regression and prolonged survival in mice. Moreover, evaluation of routes of administration found that intramuscular or intratumoral injection of mHTV-02 displayed significant therapeutic effects. In contrast, intravenous delivery of the vaccine barely showed any benefit in reducing tumor size or improving animal survival. These data together support mHTV-02 as a candidate therapeutic mRNA vaccine via specific administration routes for treating malignancies caused by HPV16 or HPV18 infections.
This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the ciliary muscle to cholinergic stimulation, dilating the pupil [mydriasis]. The stronger preparation (1%) also paralyzes accommodation. This preparation acts in 15-30 minutes, and the duration of activity is approximately 3-8 hours. Complete recovery from mydriasis in some individuals may require 24 hours. The weaker strength (0.5%) may be useful in producing mydriasis with only slight cycloplegia. Heavily pigmented irides may require more doses than lightly pigmented irides.
The present invention discloses the use of Chenopodium formosanum husk extract for improving metabolic diseases and regulating gut microbiota. Administering an effective amount of Chenopodium formosanum husk extract to an individual can effectively inhibit fat accumulation, enhance the richness and diversity of gut microbiota, strengthen the gut barrier, and regulate blood sugar. This achieves the beneficial effects of improving or preventing metabolism-related diseases and promoting gut health. The Chenopodium formosanum husk extract is also used to prepare a composition for enhancing the intestinal barrier. Specifically, administering this composition to an individual can increase the expression of intestinal ZO-1 and Occludin proteins, thereby reducing intestinal permeability or improving the increased intestinal permeability caused by a high-fat diet. This achieves the effects of strengthening gut health and reducing metabolic diseases. The invention further discloses the use of Chenopodium formosanum husk extract for preparing a composition to improve gut microbiota. In the preparation process, impurities such as dietary fiber have been removed from the Chenopodium formosanum husk extract, making it fiber-free. The use of docosanol (C26 alcohol) to prevent obesity is also disclosed in the invention. The docosanol is isolated from the aforementioned Chenopodium formosanum husk extract. The Chenopodium formosanum husk extract disclosed in this invention is obtained by extracting Chenopodium formosanum husk with an alcohol solvent, where the alcohol can be methanol.
The invention discloses a musk bone strengthening micro emulsion and a preparation method thereof. The musk bone strengthening micro emulsion is prepared from musk bone strengthening volatile oil, tween-80, absolute ethyl alcohol, a water extract and alcohol precipitation solution, musk, borneol, camphor and menthol. The volume concentration of ethyl alcohol in the water extract and alcohol precipitation solution is 90%. The musk bone strengthening micro emulsion is prepared from, by mass, 3.15% of musk bone strengthening volatile oil, 24.35% of tween-80, 12.17% of absolute ethyl alcohol, 58.50% of the water extract and alcohol precipitation solution of traditional Chinese medicines, 0.20% of musk, 0.49% of borneol, 0.49% of camphor and 0.65% of menthol. Compared with a musk bone strengthening plaster, the musk bone strengthening micro emulsion is wider in application range and more convenient to use, and enlarges the application range of the crowd. The musk bone strengthening plaster is the Chinese herbal medicine compound preparation, and after the musk bone strengthening plaster is improved to be the musk bone strengthening emulsion, references are provided for preparation of other Chinese herbal medicine compound preparation emulsions.
At Study Visit 1, subjects will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32), nesiritide) for 240 minutes. After a washout period of at least 2 weeks, subjects then present for Study Visit 2, where they will receive an IV infusion of placebo (control, normal saline) for 240 minutes.
The chemically cross-linked hydrogel is a hydrogel formed by reaction of silk with a crosslinking agent, and the crosslinking agent is a diglycidyl ether crosslinking agent. The hydrogel is obtained by dissolving silk fibers in a lithium bromide solution and crosslinking through the crosslinking agent. The hydrogel has good elasticity, and can recover more than 90% of its volume/height after being compressed for 100 cycles with a compressive deformation of 20%. The silk is very stable in matrix structure and mechanical properties. After incubation in PBS at 37° C. for 30 days, the content of β-sheets in the secondary structure elements of the silk is less than or equal to 40%, and its compressive modulus is less than or equal to 100% (with a compressive deformation of 20%). The hydrogel has good biocompatibility and adjustable biodegradability, and can be used for repairing or filling tissues in subjects.
This invention provides a method for long term pain relief. The method is basically using five novel herbal compositions, adjust the dosages according to the reason of the pain and the situation of the patient's body. The herbal composition is Corydalis Yanhusuo, E Zhu (Curcuma kwangsiensis, Rhizome), Cili Fruit (Rosa roxburghii) Extract, DL-alpha-Lipoic acid. It is preferred to diagnosis the disease and check the patient's body condition in advance. and therapeutic effects on inflammatory, sprain, gout and rheumatic arthritic diseases in human. Especially for body joint. The herbal compositions of the present invention can be used as a pharmaceutical composition, a dietary supplement or a feed. This invention also provides processes for making the herbal compositions.
This project "Getting Asian Americans INFORMED to Facilitate COVID-19 Testing and Vaccinations" is to identify and address sociocultural, ethical and behavioral barriers related to Coronavirus Disease 2019 (COVID-19) testing and vaccination to enable Asian Americans to make well-informed decisions about getting tested for COVID-19. Asian Americans have experienced high rates of COVID-19 related hospitalization and mortality rates when compared to non-Hispanic whites particularly among those who tested positive. Excess COVID-19 related deaths observed in Asian Americans are in part due to under-testing or delayed testing. Asian Americans may face multiple challenges, including sociocultural (limited English proficiency, lack of trust, excess fears and social stigma related COVID-19), ethical (lack of proven benefits of various guidelines, unequal access to testing resources), and behavioral (tobacco and e-cigarette use, other competitive behaviors) factors. The pandemic is rapidly evolving and presents urgent needs to develop highly efficient channels to communicate accurate, easily comprehensive, cultural appropriate and practical information. This application is a supplement to a parent R01 "A Family-Focused Intervention for Asian American Male Smokers," as known to the public as a community-based intervention research program "Healthy Family Project." Leveraging the community partnerships and the individual / family-based LHW intervention approaches developed by the study team, the proposed aims are: (1)Develop and evaluate "INdividual and Family-Oriented Responsive Messaging EDucation" (INFORMED) intervention in increasing knowledge about COVID-19 testing and decreasing decisional conflicts of getting tested for COVID-19. A 2-arm randomized controlled trial will compare INFORMED delivered by LHW educational outreach plus SMS text messaging to SMS text with LHW support. (2) Conduct in-depth prospective investigation of sociocultural, ethical and behavioral factors related to COVID-19 testing in Chinese, Hmong and Vietnamese American over-time. In addition, factors affecting acceptance for vaccination research trial participation and vaccination uptake and how vaccination acceptance is associated with COVID-19 testing uptake will be explored.
BACKGROUND AND OBJECTIVE: Within the context of an interdisciplinary research project, we created a cutting-edge prototype of an adaptive digital auditory training system designed for cochlear implant (CI) users. By leveraging the evidence-centered design (ECD) framework, we integrated a dynamic difficulty adjustment feature that tailors the experience to the unique performance capabilities of each individual user.
METHODS: The ECD provides a conceptual design framework suitable for complex assessments of competence and dynamic performance. In the first phase, the domain of hearing was first defined in the context of CI users. In the development phase the three core models of the ECD, the competence model, the evidence model, and the task model, were developed and implemented. In addition, an asset pool of sound and language files was created, which included comprehensive linguistic feature descriptions for calculating item difficulties.
RESULTS: Based on the requirements described, an adaptive exercise generator, an AI service, and other components were implemented. This included the development of a game environment and a dashboard for patient data management. The exercises' difficulty levels were determined based on various parameters (e.g., sound, word frequency and number of words, grammatical properties) in combination with defined task types and levels.
CONCLUSION: An adaptive digital auditory training system can help to supervise and train CI patients in a continuous, interactive process based on their individual needs. We see the ECD as an effective way to build a user-based adaptive system.
PROBLEM TO BE SOLVED: To obtain the subject composition keeping stable composition even in aqueous system, suppressing rapid reaction of each ion and capable of locally increasing pH of dentine and feeding sufficient calcium ion, etc., by including encapsulated α-tertiary calcium phosphate. SOLUTION: This composition for oral cavity comprises (A) 0.05-30 wt.%, preferably 0.2-10 wt.% encapsulated α-tertiary calcium phosphate and (B) as necessary, a fluorine compound in an amount of <2,000 ppm, preferably 50-1,500 ppm as a fluorine ion. The α-tertiary calcium phosphate has preferably 0.05-50 μm, more preferably 0.5-20 μm average particle diameter. The α-tertiary calcium can be encapsulated by mechanical, physicochemical or chemical production. The film thickness of the resultant film has preferably 3-100 μm film thickness. The component B includes preferably sodium fluoride, monofluorophosphate, etc.
Subjects with OUD will receive a baseline MRI. On the night before and day of testing, subjects with OUD will receive two doses of calcitriol (3.0mcg total), followed by PHNO injection and PET Scan for the calcitriol condition. All subjects will complete the study with both active calcitriol and a placebo control and the order these interventions are received will be randomized.
At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'walk test (6MWT), will undertake a blood sample (BNP). In the run-in period (1 week) patients will wear an Actigraph GT9X Link device which only displays the time and the battery level; all activity data will be recorded. Then participants will wear an Actigraph GT9X Link device which shows real time data about the number of steps and will upload their data via the Study Admin Mobile application for smartphones/tablets. Patients will be asked to aim for an average specified number of steps/day week by week and will receive a weekly report with results from the previous week and targets to achieve. After 8 weeks, patients will attend visit 2 (6MWT, SF36 and BNP assessment) and will carry on wearing the activated device for 8 weeks receiving weekly feedbacks and targets. After 8 weeks patients will attend visit 3 (6MWD, SF36 and BNP will be assessed) which is the end of the study.
Non-ambulatory nursing home residents \>= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A control will be a participant who mounted an adequate response as defined in primary outcomes.
6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a skin test antigen cannot be directly compared to rates in the clinical trials of another skin test antigen, and may not reflect the rates observed in practice. As with any skin test antigen, there is the possibility that broad use of Spherusol ® could reveal adverse reactions not observed in clinical trials. 

In a double-blinded placebo-controlled clinical trial conducted in areas of the U.S. endemic for C. immitis (Bakersfield, CA and Tucson, AZ), 54 adults (23-64 years of age) with a history of pulmonary coccidioidomycosis of at least 45 days duration, diagnosed by clinical findings, radiography and serological and/or mycological evidence of the disease, received a single dose of Spherusol ® concomitantly with two licensed skin test extracts (Candin ® and Trichophyton) and two controls (product diluent [thimerosal ≤0.0001%] and saline). Each intradermal injection of 0.1 mL of reagent was given at pre-determined sites on the right and left forearms. Solicited local adverse reactions and systemic adverse events occurring within 7 days after injection were recorded by study subjects via diary card. These events were also recorded on case report forms (CRFs) by study personnel during clinical visits 48 hours and 7 days following injections. Diary cards and CRFs did not record solicited local reactions by specific site. Local adverse reactions and systemic adverse events that occurred within 7 days were monitored until resolution. Reports of unsolicited adverse events and serious adverse events that occurred within 7 days after administration were collected on the diary cards or reported at study visits. 

Table 1 lists the percentage of subjects reporting solicited local reactions (at any site) and solicited systemic adverse events within 7 days following the administration of Spherusol ®, Candin ®, Trichophyton, diluent control and placebo control. 

Of subjects with severe reactions, one subject required treatment with oral corticosteroids for ulceration and swelling. Based on investigator's determination the reaction was at the site of Trichophyton injection. All severe reactions resolved without sequelae.

During the 7 days following administration two subjects reported unsolicited adverse events: one subject reported joint pain, fatigue, cough, sensitivity at a test site (test site not specified), and one subject with erythema immediately after administration (test site not specified). The intensities of these unsolicited adverse events were not recorded.

No serious adverse events or deaths were reported during the clinical study.

6.2 To report SUSPECTED ADVERSE REACTIONS, contact Nielsen BioSciences, Inc. at (855) 855-1212 or MEDWATCH, Food and Drug Administration (FDA), 5600 Fishers Lane, Rockville, MD 20852-9782. Telephone: (800) 332-1088 or www.vaers.hhs.gov.
The recruiting phase of the study includes the recruitment of patients (36 months) and is followed by 12 month of monitoring for each patient. After deciding MI and PCI treatment by physical exam, ECG and other diagnostic methods, blood samples will be collected. After undergoing PCI, samples of the same patients will be collected during hospitalization days after PCI (D0-3) according to the patient study flowchart. After hospitalization, patients will be contacted by phone call or written questionary after 30 days (D30). After 6 and 12 months, patients are reinvited for a routine rehospitalisation to perform clinical exams and ECGs. Blood and urine samples will be collected after 12 months.
IE1 will be the first group to participate in an intuitive eating program and will be required to attend five intuitive eating classes. The intuitive eating classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. This group will have an additional final assessment on the last day of the IE2's intuitive eating course. During the assessments, they will complete a questionnaire that will ask them about their body satisfaction and eating attitudes, and have their height and weight measured.
Eccentric exercise can result in exercise induced muscle damage (EIMD), which can cause an abundance of ultrastructural muscular disruption and pro-inflammatory and pro-oxidant activity in the body, leading to an impairment of muscular force production and range of motion, along with elevated pain sensitivity, increased swelling, and arterial stiffness. Pasture-raised dairy products, obtained from strictly grass-fed cows, have been shown to possess more anti-inflammatory-, antioxidant-, and antihypertensive-like biochemicals compared with conventional products (i.e., with a different nutrient composition from a diet rich in grains versus grasses). However, human research trials on these products, such as whey protein concentrate (WPC), are neglected. This study addresses this gap, with a double-blind, randomized, placebo-controlled trial that compares the effect of conventional WPC versus WPC supplementation reported to be derived from pasture-raised cows on vascular function and indirect markers of muscle damage and inflammation in response to eccentric EIMD in healthy, young, resistance-trained women and men. Thirty resistance-trained individuals will complete an intense EIMD bout consisting of eccentric barbell back squats and then will be assessed 24, 48, and 72 hours post-EIMD for muscle soreness, range of motion, maximal isometric voluntary contraction, peripheral fatigue via magnetic stimulation, countermovement jump, barbell back squat velocity, and vascular function (i.e., arterial stiffness via carotid femoral pulse wave velocity). Subjects will be grouped into a conventional WPC, pasture-raised WPC, and placebo supplementation group and consume their respective supplementation thrice daily immediately post-EIMD until the study's completion.
The present invention relates to a thrombus elimination medicine composition for treating and preventing thrombosis and a preparation method of the thrombus elimination medicine composition. A leech extract product is mainly made by leech by adopting the methods of extraction, coagulation and chromatographic fractionation, and extract products of curcuma roots and chuanxiong rhizome are made by adopting the methods of extraction and the purification of macroporous resin and using the curcuma roots and chuanxiong rhizome. The two extract products are merged and are made into preparations, such as freeze-drying powder injection, injection, tablets, capsules or soft capsules, etc. according to various kinds of preparation conventional means. The thrombus elimination medicine composition made by the present invention has the advantages of powerful thrombolytic effect, definite curative effect on diseases, such as cerebral infarction, myocardial infarction, etc. high security, efficiency of the prevention of thrombus formation, definite curative effect, controllable quality and small toxic side effect.